A 72-Year-Old Male with Advanced Renal Cell Carcinoma

Eric Jonasch, MD, presents the case of a 72-year-old male with advanced renal cell carcinoma (RCC) and discusses how recent data updates influence treatment decision-making.

EP. 1: Case Presentation: A 72-Year-Old Male with Advanced Renal Cell Carcinoma (RCC)

December 13th 2022

Eric Jonasch, MD, presents the case of a 72-year-old man with advanced renal cell carcinoma, shares his initial impression.

EP. 2: Risk Stratification and Frontline Treatments in Patients with Advanced Renal Cell Carcinoma

December 13th 2022

Dr Eric Jonasch factors that contribute to a patient’s risk status, and how a patient’s risk status impacts front-line treatment choices for patients with advanced RCC.

EP. 3: CheckMate 9ER: Long-Term Follow-Up Data

December 13th 2022

Dr Eric Jonasch reviews key efficacy and safety outcomes of the long term follow-up data from CheckMate 9ER and discusses the rationale for evaluating cabozantinib plus nivolumab in patients with advanced RCC.

EP. 4: CheckMate 9ER: Real World and Health-Related Quality of Life Outcomes

December 13th 2022

Dr Jonasch shares his perspective on CheckMate 9ER in the real-world setting and discusses the trial’s health-related quality-of-life outcomes data investigating nivolumab plus cabozantinib in advanced renal cell carcinoma treatment.

EP. 5: COSMIC-313 and Advice to Community Oncologists Treating Advanced RCC

December 13th 2022

Dr Eric Jonasch reviews key efficacy outcomes from the COSMIC 313 trial, its clinical implications, and shares advice for community oncologists treating patients with advanced renal cell carcinoma.